Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial. Issue 9 (September 2018)

• Record Type: Journal Article
• Authors: Sénat, Marie-Victoire; Affres, Helene; Letourneau, Alexandra; Coustols-Valat, Magali; Cazaubiel, Marie; Legardeur, Helene; Jacquier, Julie Fort; Bourcigaux, Nathalie; Simon, Emmanuel; Rod, Anne; Héron, Isabelle; Castera, Virginie; Sentilhes, Loic; Bretelle, Florence; Rolland, Catherine; Morin, Mathieu; Deruelle, Philippe; De Carne, Celine; Maillot, François; Beucher, Gael; Verspyck, Eric; Desbriere, Raoul; Laboureau, Sandrine; Mitanchez, Delphine; Bouyer, Jean
• Is Part Of: Obstetrical & gynecological survey. Volume 73:Issue 9(2018)
• Publication Date: 2018-09
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Surgery -- Periodicals; 618
• DOI: 10.1097/01.ogx.0000546165.11544.9d
• Languages: English
• ISSNs: 0029-7828

Abstract

Abstract : (Abstracted from JAMA 2018;319(17):1773–1780) Gestational diabetes continues to increase nationally and globally. The American Diabetes Association currently recommends insulin, the only Food and Drug Administration–approved pharmacologic agent, as first-line treatment for women with gestational diabetes mellitus requiring medications.